Zepbound®
FDA-approved tirzepatide for chronic weight management
About Zepbound®
Zepbound® is the FDA-approved brand of tirzepatide indicated for chronic weight management in adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Made by Eli Lilly, it is a once-weekly subcutaneous injection available as single-dose vials and the KwikPen pre-filled pen. Zepbound® activates both GLP-1 and GIP receptors and has produced the largest average weight loss of any FDA-approved weight-management therapy to date in head-to-head data.
Common reasons patients ask about Zepbound:
- FDA-approved with extensive trial data behind it
- Highest average weight loss in head-to-head GLP-1 data
- Approved for moderate-to-severe obstructive sleep apnea in adults with obesity
- Choice of vial or KwikPen delivery; may qualify for manufacturer savings programs
Data
What the studies show
Zepbound® is supported by the SURMOUNT phase 3 program. In SURMOUNT-1, the 15 mg dose produced an average body weight reduction of about 22.5% at 72 weeks compared to placebo. SURMOUNT-OSA later studied tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity, producing meaningful reductions in apnea-hypopnea index alongside weight loss — leading to the first FDA-approved drug for OSA in this population.
~22.5%
Average body weight reduction at 72 weeks on Zepbound® 15 mg in SURMOUNT-1
2023
FDA approval for chronic weight management
SURMOUNT-OSA
First FDA-approved medication for moderate-to-severe OSA in adults with obesity
How it works
Regulates appetite and gastric emptying
Zepbound® delivers tirzepatide, which activates both GLP-1 and GIP receptors. GLP-1 reduces appetite and slows gastric emptying; GIP adds a complementary metabolic signal that improves how the body uses glucose and lipids. Together they create a more complete appetite and metabolic effect than GLP-1 alone.
- 1
Activates GLP-1 receptors
Reduces appetite and slows gastric emptying.
- 2
Activates GIP receptors
Adds a complementary metabolic signal to improve glucose and lipid handling.
Eligibility
Who Zepbound is for
Generally a good fit for
- Adults with a BMI of 30 or higher, or 27+ with a weight-related health condition
- Patients who want a dual-pathway option for greater average weight loss
- Adults with moderate-to-severe obstructive sleep apnea and obesity (FDA-approved indication)
- Patients who want an FDA-approved branded GLP-1 with manufacturer savings access
Not appropriate for
- Pregnancy, planning pregnancy, or breastfeeding
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis or severe gastrointestinal disease
- Known hypersensitivity to tirzepatide or its components
Calculate your BMI
A starting point your provider considers alongside your full health profile.
BMI is a screening tool, not a diagnosis. Your provider will review your full health profile during the intake to determine eligibility.
Your BMI
—
Journey
What to expect & when
Weeks 1–4
- Noticeably smaller appetite and earlier fullness
- Possible mild GI side effects as your body adjusts
Weeks 5–12
- Cravings continue to quiet as the dose climbs
- Steady weight loss for most patients
Months 3+
- Many patients continue losing through 9–12 months
- Maintenance dosing is personalized once goals are reached
Ongoing
- Continued monitoring, dose adjustments, and cycling decisions guided by your PreventiveMD provider
Side effects
Safety & side effects
Zepbound® shares the GLP-1-class side-effect profile, with GI symptoms most common. Pacing titration is the single biggest lever for tolerability.
Common
- Nausea, especially during titration
- Diarrhea or constipation
- Bloating or reflux
- Decreased appetite
- Injection-site reactions
Less common but serious
- Pancreatitis
- Gallbladder disease, including gallstones
- Kidney injury from dehydration
- Possible thyroid C-cell tumors (class warning based on rodent studies)
If you have questions about whether Zepbound is right for you, your PreventiveMD provider will review your full health history once you get started.
Dosing
How to take Zepbound
Zepbound® vials are titrated from 2.5 mg weekly to a maintenance dose of 5, 7.5, 10, 12.5, or 15 mg weekly, with increases every four weeks as tolerated. Specific dose is set by your provider based on goals and tolerance.
How to inject
- 1Wash your hands thoroughly.
- 2Choose an injection site your provider recommended, rotating to a different spot than your last injection.
- 3Clean the site with an alcohol wipe and let it dry completely, then inject as instructed.
- 4Place the used needle and syringe in your sharps container.
The Zepbound® KwikPen is a multi-dose pre-filled pen titrated on the same weekly schedule as the vials: starting at 2.5 mg once weekly, increasing in 2.5 mg steps every four weeks as tolerated. Maintenance doses are 5, 7.5, 10, 12.5, or 15 mg weekly; for OSA, the FDA-approved maintenance is 10 mg or 15 mg weekly. Specific dose is set by your provider based on goals and tolerance.
How to inject
- 1Let the pen reach room temperature for about 15 minutes before injecting.
- 2Dial the prescribed dose using the dose knob until it clicks into place.
- 3Choose a fresh site, clean it, and press the pen firmly against the skin to deliver.
- 4Replace the cap and store as instructed; dispose of the pen in a sharps container when empty.
Seek emergency care immediately if you experience difficulty breathing or swallowing, swelling of the face, lips, tongue, or throat, hives or a widespread rash, dizziness or fainting, or a rapid heartbeat. These can be signs of a serious allergic reaction.
Pricing
Transparent pricing, no surprises
Loading pricing…
FAQs
In case you were wondering
Both contain tirzepatide. Zepbound® is an FDA-approved finished drug product manufactured by Eli Lilly with standardized dosing and delivery. Compounded tirzepatide is prepared by a pharmacy under physician supervision for individual patients — a different regulatory pathway.
Vials may be more cost-effective in some pricing programs; the KwikPen offers a more streamlined injection experience without drawing from a vial. Your provider can help you choose based on cost, convenience, and comfort.
Coverage varies by plan and indication. Many commercial plans cover Zepbound® for qualifying patients; manufacturer savings programs can lower out-of-pocket cost. Our team can help you check coverage.
Most patients notice reduced appetite within the first two weeks and visible weight loss within 1–2 months. Average results in SURMOUNT-1 continued building through 72 weeks.
Our content is reviewed by our medical team and draws from peer-reviewed clinical research, FDA prescribing information, and recognized clinical guidelines. The primary sources cited on this page:
- [TODO: Pivotal clinical trial citation for Zepbound]
[TODO: Authors, journal, year (DOI when available)]
- [TODO: Mechanism of action / review article]
[TODO: Authors, journal, year (DOI when available)]
- [TODO: FDA prescribing information / regulatory source]
- [TODO: Clinical society guideline or consensus statement]
How to get started
Preventive care begins here
Hi, I’m Eve, your care concierge. Ready to start when you are.
Currently, we are not yet available in Alaska, Kentucky, Louisiana, Mississippi, New Jersey, New Mexico, Rhode Island, and West Virginia. Get notified once we are.
Complete a 5-minute questionnaire
Choose your protocols
Self-pay checkout
Your provider prescribes if it’s the right fit
By starting, you agree to our Terms of Use and acknowledge our Privacy Policy.
